Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 13
2003 10
2004 10
2005 15
2006 17
2007 35
2008 50
2009 51
2010 54
2011 53
2012 61
2013 58
2014 70
2015 66
2016 65
2017 74
2018 72
2019 63
2020 65
2021 47
2022 28
2023 14
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

843 results

Results by year

Filters applied: . Clear all
Page 1
Combined hepatocellular-cholangiocarcinoma compared to hepatocellular carcinoma and intrahepatic cholangiocarcinoma: Different survival, similar recurrence: Report of a large study on repurposed databases with propensity score matching.
Amory B, Goumard C, Laurent A, Langella S, Cherqui D, Salame E, Barbier L, Soubrane O, Farges O, Hobeika C, Kawai T, Regimbeau JM, Faitot F, Pessaux P, Truant S, Boleslawski E, Herrero A, Mabrut JY, Chiche L, Di Martino M, Rhaiem R, Schwarz L, Resende V, Calderaro J, Augustin J, Caruso S, Sommacale D, Hofmeyr S, Ferrero A, Fuks D, Vibert E, Torzilli G, Scatton O, Brustia R; AFC-ICC-2009, AFC-LLR-2018, and PRS-2019 Study Group. Amory B, et al. Surgery. 2024 Feb;175(2):413-423. doi: 10.1016/j.surg.2023.09.040. Epub 2023 Nov 18. Surgery. 2024. PMID: 37981553
Safety and efficacy of neoadjuvant chemoradiotherapy with moderately hypofractionated intensity-modulated radiotherapy for resectable pancreatic cancer: A prospective, open-label, phase II study.
Masui T, Nagai K, Anazawa T, Kasai Y, Yogo A, Yoshimura M, Mizowaki T, Uza N, Fukuda A, Matsumoto S, Kanai M, Isoda H, Kawaguchi Y, Uemoto S, Hatano E. Masui T, et al. Among authors: uemoto s. Cancer Med. 2023 Sep;12(18):18611-18621. doi: 10.1002/cam4.6470. Epub 2023 Aug 30. Cancer Med. 2023. PMID: 37649318 Free PMC article.
MicroRNAs associated with postoperative outcomes in patients with limited stage neuroendocrine carcinoma of the esophagus.
Okumura T, Fujii T, Terabayashi K, Kojima T, Takeda S, Kashiwada T, Toriyama K, Hijioka S, Miyazaki T, Yamamoto M, Tanabe S, Shirakawa Y, Furukawa M, Honma Y, Hoshino I, Nabeya Y, Yamaguchi H, Uemoto S, Shimada Y, Matsubara H, Ozawa S, Makuuchi H, Imamura M. Okumura T, et al. Among authors: uemoto s. Oncol Lett. 2023 May 12;26(1):276. doi: 10.3892/ol.2023.13862. eCollection 2023 Jul. Oncol Lett. 2023. PMID: 37274462 Free PMC article.
Propensity Score Matching Analysis of the Safety of Completion Total Pancreatectomy for Remnant Pancreatic Tumors Versus that of Initial Total Pancreatectomy for Primary Pancreatic Tumors.
Kanemitsu E, Masui T, Nagai K, Anazawa T, Kasai Y, Yogo A, Ito T, Mori A, Takaori K, Uemoto S, Hatano E. Kanemitsu E, et al. Among authors: uemoto s. Ann Surg Oncol. 2023 Jul;30(7):4392-4406. doi: 10.1245/s10434-023-13309-6. Epub 2023 Mar 18. Ann Surg Oncol. 2023. PMID: 36933081
843 results